Evasion of targeted cancer therapy through stem-cell-like reprogramming

Kristine M. Wadosky; Leigh Ellis; David W. Goodrich

doi:10.1080/23723556.2017.1291397

Evasion of targeted cancer therapy through stem-cell-like reprogramming

Kristine M. Wadosky, Leigh Ellis, David W. Goodrich^*

^*Corresponding author for this work

Surgery

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Prostate cancer variants expressing alternative lineage markers appear at relapse from antiandrogen therapy. We show that loss of the retinoblastoma (RB1) and tumor protein 53 (TP53) genes drives expression of stem cell reprogramming factors, lineage plasticity, and antiandrogen resistance. Epigenetic manipulation restores antiandrogen sensitivity—suggesting an approach for treating lethal prostate cancers.

Original language	English
Article number	e1291397
Journal	Molecular and Cellular Oncology
Volume	4
Issue number	2
DOIs	https://doi.org/10.1080/23723556.2017.1291397
State	Published - 4 Mar 2017

Keywords

Epigenetic reprogramming
mouse models
prostate cancer
therapeutic resistance
tumor suppressor genes

Access to Document

10.1080/23723556.2017.1291397

Cite this

@article{05f25d16e3534a39bfc726e16f7b1677,

title = "Evasion of targeted cancer therapy through stem-cell-like reprogramming",

abstract = "Prostate cancer variants expressing alternative lineage markers appear at relapse from antiandrogen therapy. We show that loss of the retinoblastoma (RB1) and tumor protein 53 (TP53) genes drives expression of stem cell reprogramming factors, lineage plasticity, and antiandrogen resistance. Epigenetic manipulation restores antiandrogen sensitivity—suggesting an approach for treating lethal prostate cancers.",

keywords = "Epigenetic reprogramming, mouse models, prostate cancer, therapeutic resistance, tumor suppressor genes",

author = "Wadosky, {Kristine M.} and Leigh Ellis and Goodrich, {David W.}",

note = "Publisher Copyright: {\textcopyright} 2017, {\textcopyright} 2017 Taylor & Francis Group, LLC.",

year = "2017",

month = mar,

day = "4",

doi = "10.1080/23723556.2017.1291397",

language = "English",

volume = "4",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Evasion of targeted cancer therapy through stem-cell-like reprogramming

AU - Wadosky, Kristine M.

AU - Ellis, Leigh

AU - Goodrich, David W.

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Prostate cancer variants expressing alternative lineage markers appear at relapse from antiandrogen therapy. We show that loss of the retinoblastoma (RB1) and tumor protein 53 (TP53) genes drives expression of stem cell reprogramming factors, lineage plasticity, and antiandrogen resistance. Epigenetic manipulation restores antiandrogen sensitivity—suggesting an approach for treating lethal prostate cancers.

AB - Prostate cancer variants expressing alternative lineage markers appear at relapse from antiandrogen therapy. We show that loss of the retinoblastoma (RB1) and tumor protein 53 (TP53) genes drives expression of stem cell reprogramming factors, lineage plasticity, and antiandrogen resistance. Epigenetic manipulation restores antiandrogen sensitivity—suggesting an approach for treating lethal prostate cancers.

KW - Epigenetic reprogramming

KW - mouse models

KW - prostate cancer

KW - therapeutic resistance

KW - tumor suppressor genes

UR - http://www.scopus.com/inward/record.url?scp=85049612453&partnerID=8YFLogxK

U2 - 10.1080/23723556.2017.1291397

DO - 10.1080/23723556.2017.1291397

M3 - Article

AN - SCOPUS:85049612453

SN - 2372-3556

VL - 4

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 2

M1 - e1291397

ER -